High CLEC-2 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma
Metrics: PDF 2058 views | HTML 2116 views | ?
Ying Xiong1,*, Li Liu1,*, Yu Xia1,*, Jiajun Wang1, Wei Xi1, Qi Bai1, Yang Qu1, Qilai Long1, Jiejie Xu2, Jianming Guo1
1Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
2Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China
*These authors contributed equally to this work
Jiejie Xu, email: [email protected]
Jianming Guo, email: [email protected]
Keywords: c-type lectin-like receptor 2, clear cell renal cell carcinoma, prognostic factor, overall survival, recurrence-free survival
Received: May 31, 2016 Accepted: August 13, 2016 Published: August 25, 2016
We enrolled a total of 277 patients who received nephrectomy due to clear cell renal cell carcinoma (ccRCC) in Zhongshan Hospital from Jan 2005 to Jun 2007. Immunohistochemistry was performed to evaluate the impact of CLEC-2 positive cell infiltration on the overall survival (OS) and recurrence-free survival (RFS) of patients with ccRCC. Kaplan-Meier analysis showed that high CLEC-2 positive cell infiltration in tumor tissue indicated poorer OS and RFS (OS, p < 0.001; RFS, p = 0.002). High CLEC-2 positive cell infiltration is also an independent risk factor for OS and RFS in multivariate analyses (OS, p = 0.004; RFS, p = 0.009). CLEC-2 positive cell infiltration could also stratify ccRCC patients’ survival with University of California Integrated Staging System (UISS) stratum in the mediate-risk and high-risk groups. We constructed two nomograms incorporating parameters derived from multivariate analyses to predict patients’ OS and RFS (OS, c-index 0.813; RFS, c-index 0.716). In conclusion, high CLEC-2 positive cell infiltration in ccRCC is an independent adverse prognostic factor for patients, and established nomograms based on this information could help predict ccRCC patients’ OS and RFS.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.